

ERRATUM

Catia Marzolini · Laurent A. Decosterd · Fei Shen
 Marc Gander · Serge Leyvraz · Jean Bauer
 Thierry Buclin · Jérôme Biollaz · Ferdy Lejeune

Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration

In: Cancer Chemother Pharmacol (1998) 42: 433–440

In the Reference section of the above paper on p. 440 Reference no. 10 (Khayat et al.) was erroneously omitted when the authors' corrections were carried out. The subsequent numbering was erroneously changed as well. Thus, the reference numbers (starting with Ref. no. 10) are mismatched with the reference titles and cannot be identified in the paper itself. The correct list of References and numbers should read as follows:

References

- Khayat D, Lokiec F, Bizzani JP, Weil M, Meeus L, Sellani M, Rousse J, Bonzet P, Jacquillant C (1987) Phase I clinical study of the new amino acid-linked nitrosourea, S10036, administered on a weekly schedule. *Cancer Res* 47: 6782–6785
- Kleeberg UR, Engel E, Israels P, Brocker EB, Tilgen W, Kennes C, Gerard B, Lejeune F, Glabbeke MV, Lentz MA (1995) Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumor load and treatment effectiveness. A multicentre phase II trial of the EORTC-Melanoma Cooperative Group (MCG). *Melanoma Res* 5: 195–200
- Khayat D, Giroux B, Berille J, Cour V, Gerard B, Sarkany M, Bertrand P, Bizzari JP (1994) Fotemustine in the treatment of brain primary tumors and metastases. *Cancer Invest* 12: 414–420
- Lee SM, Margison GP, Woodcock AA, Thatcher N (1993) Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma. *Br J Cancer* 67: 1356–1360
- Aamdal S, Gerard B, Bohman T, D'Incalci M (1992) Sequential administration of dacarbazine and fotemustine in patients with disseminated malignant melanoma – an effective combination with unexpected toxicity. *Eur J Cancer* 28: 447–450
- Gerard B, Aamdal S, Lee S, Leyvraz S, Lucas C, D'Incalci M, Bizzarri JP (1993) Activity and unexpected lung toxicity of the sequential administration of two alkylating agents – dacarbazine and fotemustine – in patients with melanoma. *Eur J Cancer* 5: 711–719
- Tsang LLH, Farmer PB, Gescher A, Slack JA (1990) Characterisation of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicity. *Cancer Chemother Pharmacol* 26: 429–436
- Newlands ES, Blackledge GRP, Slack JA, Rustin CSS, Smith DB, Stuart NSA, Quaterman CP, Hoffman R, Stevens MFG, Brompton MH, Gibson AC (1992) Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). *Br J Cancer* 65: 287–291
- O'Reilly SM, Newlands ES, Glaser MG, Brompton M, Rice-Edwards JM, Illingworth RD, Richards PG, Kennard C, Colquhoun IR, Lewis P, Stevens MFG (1993) Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumors. *Eur J Cancer* 29A: 940–942
- Dhodapkar M, Reid J, Ames J, Buckner MM, Burch JC, Rubin PA (1994) Phase I clinical trial and pharmacokinetics of temozolomide (NSC 362856). *Proc Am Assoc Cancer Res* 35: 463
- Bleehen NM, Newlands ES, Lee SM, Thatcher N, Selby P, Calvert AH, Rustin GIS, Brompton M, Stevens MFG (1995) Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. *J Clin Oncol* 13: 910–913
- Newlands ES, O'Reilly SM, Glaser MG, Bower M, Evans H, Brock C, Brompton MH, Colquhoun I, Lewis P, Rice-Edwards JM, Illingworth RD, Richards PG (1996) The Charing Cross Hospital experience with temozolomide in patients with gliomas. *Eur J Cancer* 32A: 2236–2241
- Newlands ES, Stevens MFG, Wedge SR, Wheelhouse RT, Brock C (1997) Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. *Cancer Treat Rev* 23: 35–61

C. Marzolini¹ · L.A. Decosterd (✉) · F. Shen²

T. Buclin · J. Biollaz
 Division de Pharmacologie Clinique,
 BH18-218, Département de médecine,
 Centre Hospitalier Universitaire Vaudois,
 rue du Bugnon 46, CH-1011 Lausanne, Switzerland
 e-mail: Laurentarthur.Decosterd@chuv.hospvd.ch
 Tel.: +41-21-314 42 72; Fax: +41-21-314 42 88

M. Gander · S. Leyvraz · J. Bauer · F. Lejeune
 Centre Pluridisciplinaire d'Oncologie,
 Centre Hospitalier Universitaire Vaudois,
 rue du Bugnon 46, CH-1011 Lausanne, Switzerland

Present addresses:

¹ SOS Pharmaciens, rue des Cordiers 4,
 CH-1207 Geneva, Switzerland

² Laboratory for Experimental Oncology,
 RR 337, Indiana University School of Medicine,
 702 Barnhill Drive, Indianapolis, IN 46202-5119, USA